AIML Aligns Leadership for Growth and Shareholder Value Creation
AI/ML Innovations Inc. (AIML) has announced significant leadership changes to drive growth and commercialization. Paul Duffy, the company's CEO, has been appointed Executive Chairman of the Board, while Peter Kendall, President and Chief Commercialization Officer, joins as a new board member. Former Executive Chair Mark Orsmond and board member Michael Nemirow have transitioned to strategic advisor roles.
These changes align with AIML's strategic focus on commercial execution, market penetration, and strategic partnerships in AI-driven healthcare technologies. Orsmond and Nemirow will continue supporting corporate development initiatives, strategic partnerships, and commercialization strategies in their advisory capacities.
AI/ML Innovations Inc. (AIML) ha annunciato importanti cambiamenti nella leadership per promuovere la crescita e la commercializzazione. Paul Duffy, CEO dell'azienda, è stato nominato Presidente Esecutivo del Consiglio, mentre Peter Kendall, Presidente e Chief Commercialization Officer, entra come nuovo membro del consiglio. L'ex Presidente Esecutivo Mark Orsmond e il membro del consiglio Michael Nemirow sono passati a ruoli di consulenti strategici.
Questi cambiamenti sono in linea con il focus strategico di AIML sull'esecuzione commerciale, la penetrazione del mercato e le partnership strategiche nelle tecnologie sanitarie guidate dall'IA. Orsmond e Nemirow continueranno a supportare le iniziative di sviluppo aziendale, le partnership strategiche e le strategie di commercializzazione nelle loro capacità di consulenti.
AI/ML Innovations Inc. (AIML) ha anunciado cambios significativos en el liderazgo para impulsar el crecimiento y la comercialización. Paul Duffy, CEO de la empresa, ha sido nombrado Presidente Ejecutivo de la Junta, mientras que Peter Kendall, Presidente y Director de Comercialización, se une como nuevo miembro de la junta. El ex Presidente Ejecutivo Mark Orsmond y el miembro de la junta Michael Nemirow han pasado a roles de asesores estratégicos.
Estos cambios están alineados con el enfoque estratégico de AIML en la ejecución comercial, la penetración de mercado y las asociaciones estratégicas en tecnologías de salud impulsadas por IA. Orsmond y Nemirow continuarán apoyando las iniciativas de desarrollo corporativo, las asociaciones estratégicas y las estrategias de comercialización en sus capacidades de asesoría.
AI/ML Innovations Inc. (AIML)는 성장과 상업화를 촉진하기 위한 중요한 리더십 변화를 발표했습니다. Paul Duffy는 회사의 CEO에서 이사회 의장으로 임명되었으며, Peter Kendall는 사장 겸 상업화 책임자로서 새로운 이사로 합류합니다. 전 이사회 의장 Mark Orsmond와 이사 Michael Nemirow는 전략 자문 역할로 전환되었습니다.
이러한 변화는 AIML의 상업 실행, 시장 침투 및 AI 기반 헬스케어 기술에 대한 전략적 파트너십에 대한 전략적 초점과 일치합니다. Orsmond와 Nemirow는 자문 역할에서 기업 개발 이니셔티브, 전략적 파트너십 및 상업화 전략을 계속 지원할 것입니다.
AI/ML Innovations Inc. (AIML) a annoncé des changements significatifs dans sa direction pour stimuler la croissance et la commercialisation. Paul Duffy, le PDG de l'entreprise, a été nommé Président Exécutif du Conseil, tandis que Peter Kendall, Président et Directeur de la Commercialisation, rejoint le Conseil en tant que nouveau membre. L'ancien Président Exécutif Mark Orsmond et le membre du Conseil Michael Nemirow ont été transférés à des rôles de conseillers stratégiques.
Ces changements s'alignent sur l'objectif stratégique d'AIML en matière d'exécution commerciale, de pénétration du marché et de partenariats stratégiques dans les technologies de santé pilotées par l'IA. Orsmond et Nemirow continueront de soutenir les initiatives de développement d'entreprise, les partenariats stratégiques et les stratégies de commercialisation dans leurs capacités de conseillers.
AI/ML Innovations Inc. (AIML) hat bedeutende Veränderungen in der Führung angekündigt, um Wachstum und Kommerzialisierung voranzutreiben. Paul Duffy, der CEO des Unternehmens, wurde zum Executive Chairman des Vorstands ernannt, während Peter Kendall, Präsident und Chief Commercialization Officer, als neues Vorstandsmitglied hinzukommt. Der ehemalige Executive Chair Mark Orsmond und das Vorstandsmitglied Michael Nemirow haben sich in strategische Beraterrollen zurückgezogen.
Diese Veränderungen stehen im Einklang mit AIMLs strategischem Fokus auf kommerzielle Ausführung, Marktdurchdringung und strategische Partnerschaften im Bereich der KI-gesteuerten Gesundheitstechnologien. Orsmond und Nemirow werden weiterhin die Unternehmensentwicklungsinitiativen, strategischen Partnerschaften und Kommerzialisierungsstrategien in ihren beratenden Funktionen unterstützen.
- Strategic board restructuring to enhance commercial focus and execution
- Retention of former board members as strategic advisors maintains valuable expertise
- Diversified investment portfolio in AI-driven healthcare technologies
- None.
Paul Duffy Appointed Executive Chairman of the Board
Peter Kendall Joins Board
Seasoned Advisors Mark Orsmond and Michael Nemirow to Support AIML's Corporate Development Initiatives
VANCOUVER, BC / ACCESS Newswire / March 14, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce key updates to its Board of Directors ("Board") as the Company enters an exciting new phase of growth and commercialization.
Paul Duffy, AIML's Chief Executive Officer, and Peter Kendall, AIML's President and Chief Commercialization Officer, have both been appointed to the Board. Mr. Duffy has also assumed the role of Executive Chairman, Simultaneously, Mark Orsmond, outgoing Executive Chair of the Board, and Michael Nemirow have stepped down from the Board and continue their involvement as strategic advisors.
These changes reflect AIML's strategic commitment to aligning with the Company's forward-looking focus on commercial execution, market penetration, and strategic partnerships. As AIML continues to advance its innovative portfolio of AI-driven healthcare technologies, this Board realignment ensures the Company is structured to accelerate growth, provide direct industry experience, and drive shareholder value.
Paul Duffy, CEO and newly appointed Chairman of the Board, commented:
"We are entering an exciting new chapter at AIML, one defined by focus, execution, and scalable impact. Strengthening our Board with more industry participants to enhance a commercialization lens is a key part of our strategic evolution, and I'm honored to now serve in a governance capacity alongside Peter Kendall. I would like to express my deep gratitude to both Mark and Michael for their dedication, insights, and leadership during a foundational period for the Company. In particular, we are very grateful to Mark for the top-tier medical and professional team that is now part of our Company, and I look forward to continuing to work closely with him in his new advisory role."
As part of this transition, Mark Orsmond and Michael Nemirow will continue to play a pivotal role in the Company's growth trajectory, supporting corporate development initiatives, strategic partnerships, and commercialization strategies.
AIML remains steadfast in its mission to deliver breakthrough solutions at the intersection of artificial intelligence and human health. These leadership transitions mark a meaningful step forward in realizing that vision.
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
Contact:
Blake Fallis
(778) 405-0882
info@aiml-innovations.com
About AI/ML Innovations Inc. https://aiml-innovations.com/
AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its wholly-owned subsidiaries, Quantum Sciences Ltd. and NeuralCloud Solutions Inc, strategic partnerships with Health Gauge Inc. (
On behalf of the Board of Directors:
Paul Duffy, Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
The Canadian Securities Exchange has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains "forward- looking statements" within the meaning of the securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will be issued as a result of a pending patent application or, if issued, whether it will be issued in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time at sedarplus.ca. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. The Company is not responsible for the contents of third- party websites.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire
FAQ
What leadership changes did AIML (AIMLF) announce in March 2024?
How will the new board structure impact AIML's business strategy?
What roles will former board members maintain at AIML (AIMLF)?
What is AIML's current investment portfolio structure?
